| Literature DB >> 28790965 |
Mira E Ossen1, Robert Stokroos2, Herman Kingma2,3, Joost van Tongeren2, Vincent Van Rompaey4,5, Yasin Temel6, Raymond van de Berg2,3.
Abstract
BACKGROUND: Superior canal dehiscence syndrome (SCDS) can be treated surgically in patients with incapacitating symptoms. However, the ideal treatment has not been determined.Entities:
Keywords: middle fossa; plugging; resurfacing; superior canal dehiscence syndrome; transmastoid
Year: 2017 PMID: 28790965 PMCID: PMC5523725 DOI: 10.3389/fneur.2017.00347
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Risk of bias per study.
| Study ID | In- and exclusion criteria | Selection bias | Participant characteristics | Blinding of participants, personnel | Reproducibility (techniques well described) | Correction for confounding | Follow-up | Quality of outcome measure | Loss to follow-up | Information bias | Conflict of interest | Selective reporting of outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remenschneider et al. ( | + | − | + | − | + | − | + | + | + | − | + | +/− |
| Chung et al. ( | +/− | − | + | − | + | − | +/− | − | + | − | + | + |
| Thomeer et al. ( | + | − | + | − | + | − | + | + | + | − | +/− | ± |
| Goddard and Wilkinson ( | + | − | +/− | − | + | − | + | + | + | − | +/− | ± |
| Ward et al. ( | + | − | +/− | − | + | − | +/− | + | + | − | +/− | ± |
| Agrawal et al. ( | + | − | +/− | − | + | − | +/− | + | + | − | +/− | ± |
| Crane et al. ( | + | − | + | − | + | − | + | + | + | − | +/− | ± |
| Crane et al. ( | + | − | + | − | + | − | + | + | + | − | +/− | ± |
| Carey et al. ( | + | +/− | ± | − | + | − | +/− | + | − | +/− | + | + |
| Phillips et al. ( | + | − | + | − | + | − | + | + | + | − | +/− | + |
| Limb et al. ( | + | − | − | − | + | − | +/− | + | + | − | +/− | + |
| Hillman et al. ( | + | − | + | − | + | − | + | − | + | − | +/− | − |
| Van Haesendonck et al. ( | + | − | + | − | + | − | +/− | + | + | − | +/− | − |
| Beyea et al. ( | + | − | +/− | − | + | − | +/− | + | + | − | + | − |
| Agrawal and Parnes ( | + | − | +/− | − | + | − | +/− | + | + | − | + | +/− |
| Fiorino et al. ( | + | − | + | − | + | − | + | +/− | + | − | +/− | + |
| Amoodi et al. ( | + | − | − | − | + | − | + | +/− | + | − | +/− | ± |
| Lundy et al. ( | + | − | +/− | − | + | − | + | + | + | − | +/− | + |
| Silverstein et al. ( | + | − | +/− | − | −/+ | − | +/− | ± | + | − | +/− | + |
Assessment tools for subjective and objective outcome measures.
| Technique | Study | Assessment subjective symptoms | Assessment objective measurements | Time of measurement post surgery | Adverse effects | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Audiometrics | Vestibular-evoked myogenic potentials (VEMPs) | Head impulse test | Calorics | Induced nystagmus | ||||||
| Middle fossa approach | P | Remenschneider et al. ( | Health utility value, autophony index (AI), dizziness handicap inventory (DHI), and Hearing Handicap Inventory | x | x | x | x | x | 3 months | x |
| P + R | Chung et al. ( | Anamnesis | x | x | x | x | x | x | x | |
| Thomeer et al. ( | Anamnesis | Cervical vestibular-evoked myogenic potentials (cVEMPs): threshold, amplitude | x | x | x | D7 and 1 month | Reported | |||
| Goddard and Wilkinson ( | Anamnesis | x | x | x | x | x | Reported | |||
| Ward et al. ( | x | x | x | x | x | x | Reported | |||
| Agrawal et al. ( | x | x | x | 1. Clinical | x | x | x | x | ||
| 2. Search coil: horizontal canals | ||||||||||
| Crane et al. ( | AI, DHI | cVEMPs: thresholds | x | x | x | 3 months: AI, DHI | Reported | |||
| Crane et al. ( | DHI | cVEMPs: thresholds, auditory stimuli | x | x | x | 3 months: DHI | x | |||
| Carey et al. ( | Anamnesis | x | x | Search coil: all canals | x | x | 1.5–7 months | Reported | ||
| Phillips et al. ( | Anamnesis | cVEMPs: thresholds | x | x | x | 4 months | Reported | |||
| Limb et al. ( | x | x | x | x | x | x | x | |||
| R | Hillman et al. ( | Anamnesis | x | x | x | x | >3 months | x | ||
| Transmastoid approach | P | Van Haesendonck et al. ( | Anamnesis | x | x | x | x | x | Reported | |
| Beyea et al. ( | Anamnesis | x | x | x | x | x | x | Reported | ||
| Agrawal and Parnes ( | Anamnesis | x | x | x | x | x | Reported | |||
| P + R | Fiorino et al. ( | Anamnesis | VEMPs: thresholds | x | Procedure not described | Sound and pressure induced, not described. | 1.5–2 months | Reported | ||
| R | Amoodi et al. ( | Anamnesis | x | x | x | Sound and pressure induced, procedure not described. | Not reported, follow-up varied between 1.5 and 4 years | Reported | ||
| Lundy et al. ( | Scale from “worsening” to “much better” | x | x | x | x | x | >3 months | x | ||
| Transcanal approach | RW | Silverstein et al. ( | Superior canal dehiscence syndrome questionnaire | x | x | x | x | x | x | x |
| (7-point Likert type scale) | ||||||||||
Subjective improvement in affected ears.
| Study | Improvement of symptoms in affected ears | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HA | T | AP | H | AF | NIV | PIV | GD | Headache | Quality of life | |||
| Middle fossa | P | Remenschneider et al. ( | x | x | Pre: 32.7 (28.0) Post: 4.8 (8.3) | Pre: 41.8 (27.9) Post: 26.7 (30.2) | x | x | x | Pre: 48.7 (23.4) Post: 38.2 (30.7) | x | Pre: 0.65 (0.12) Post: 0.79 (0.12) |
| P + R | Chung et al. ( | x | Pre: 12/18 Post: 3/18 Developed: 1/3 | Pre: 16/18 Post: 5/18 | Pre: 10/18 Post: 4/10 | Pre: 7/18 Post: 3/18 Developed: 2/3 | Pre: 13/18 Post: 6/18 Developed: 1/6 | Pre: 13/18 Post: 6/18 Developed: 1/6 | Pre: 11/18 Post: 5/18 Developed: 2/5 | Pre: 5/18 Post: 4/18 Developed: 1/4 | x | |
| Thomeer et al. ( | x | Resolved: Pulsatile: 12/12 Non-pulsatile: 0/1 | Resolved: 9/9 | x | Resolved: 6/6 | Resolved: 14/16 | Resolved: 10/10 | Resolved: 14/16 | x | x | ||
| Goddard and Wilkinson ( | x | x | Resolved: 12/15 | x | Resolved: 16/20 | Resolved: 8/8 | Resolved: 8/11 | Resolved: 16/24 | x | x | ||
| Ward et al. ( | x | x | x | x | x | x | x | x | x | x | ||
| Agrawal et al. ( | x | x | x | x | x | x | x | x | x | x | ||
| Crane et al. ( | Pre: 42 ± 27 (range 0–86) Post: 9 ± 22 (range 0–82) | Pre: 48.22 Post: 27.77 | x | x | ||||||||
| Crane et al. ( | x | x | x | x | x | x | x | Pre: 44 ± 24 Post: 18 ± 15 Decreased: 17/19 Increased: 2/19 | x | x | ||
| Carey et al. ( | x | x | x | x | x | Resolved: 19/19 | Resolved: 19/19 | x | x | x | ||
| Phillips et al. ( | Improved: 5/5 | Transient increase: 4/5 Improved: 5/5 | x | x | ||||||||
| Limb et al. ( | x | x | x | x | x | x | x | x | x | x | ||
| R | Hillman et al. ( | x | Resolved: Pulsatile: 2/3 Non-pulsatile: – | x | x | x | x | Resolved: 12/12 | Resolved: 12/13 | x | x | |
| Transmastoid | P | Van Haesendonck et al. ( | Resolved: 6/8 | Resolved: Pulsatile: 6/9 Non-pulsatile: – | Resolved: 11/12 | x | x | Resolved: 4/5 | Resolved: 2/5 Developed: 1/5 | x | x | x |
| Beyea et al. ( | Resolved: 1/1 | Resolved: Pulsatile: 10/10 Non-pulsatile: – | x | Improved: 2/16 Preserved: 14/16 | x | x | x | Transient increase: 16/16 | x | x | ||
| Agrawal and Parnes ( | x | x | Resolved: 1/1 | x | x | Resolved: 3/3 | Resolved: 1/1 | Transient increase: 3/3 Resolved: 3/3 | x | x | ||
| P + R | Fiorino et al. ( | x | x | x | x | x | Improved: 6/6 | Improved: 6/6 | Improved: 6/6 | x | x | |
| R | Amoodi et al. ( | x | x | x | x | x | x | x | Transient increase: 4/4 | x | x | |
| Lundy et al. ( | x | x | x | x | x | x | x | Questionnaire: Much better: 29 Some better: 5 Same: 2 Worse: 1 | x | x | ||
| Transcanal | RW | Silverstein et al. ( | x | Pulsatile: Pre: 4.6 (SD 2.0) Post: 2.2 (SD 1.4) (1 = not bothered, 7 = disabled) Non-pulsatile: – | Autophony: Pre: 4.6 (SD 1.9) Post: 2.2 (SD 1.7) Bone conduction sensitivity: Pre: 4.5 (SD 2.0) Post: 2.0 (SD 1.5) | Pre: 2.5 (SD 1.6) Post: 2.2 (SD 1.4) | Pre: 4.2 (SD 1.6) Post: 2.5 (SD 1.4) | Pre: 5.4 (SD 1.5) Post: 2.3 (SD 1.3) | Pre: 3.6 (SD 1.3) Post: 2.0 (SD 1.3) | Pre: 4.2 (SD 1.7) Post: 2.1 (SD 1.2) | x | x |
Objective improvement of auditory and vestibular function.
| Study | Results objective measures postoperative relative to preoperative | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Audiometry | Vestibular-evoked myogenic potentials (VEMPs) | Head impulse test | Calorics | Induced nystagmus | Time | Adverse effects | Hospital stay (days) | |||
| Middle Fossa | P | Remenschneider et al. ( | x | x | x | x | x | x | x | |
| P + R | Chung et al. ( | x | x | x | x | x | x | x | x | |
| Thomeer et al. ( | Air conduction (AC): mean ↑: +7.4 dB (SD 7.7) Bone conduction (BC): mean ↓: −2.5 dB (SD 7.2) Air bone gap (ABG): mean ↓: −9.0 dB (SD 10.9) AC: mean ↑: +4.5 dB (SD 5.3) BC: mean ↓: −0.2 dB (SD 5.6) ABG: mean ↓: −4.7 dB (SD 6.9) 7 days: +11.6−dB 1–6 months: −2.2 dB | Cervical vestibular-evoked myogenic potential (cVEMP) Thresholds (n = 14) Pre Mean: 76.1 dB (range 70–90) (abnormal <90 dB nHL) Post mean: 94.4 dB (range 80–100) ( Not further defined | x | x | x | x | x | 7.8 (range 4–13) ICU: 2.7 (2–8) | ||
| Goddard and Wilkinson ( | 0.5–3 kHz AC ( Pre mean pure-tone average (PTA): 21.1 dB (SD 21.6) Post mean PTA: 22.5 dB (SD 16.7) BC ( Pre mean PTA: 15.6 dB (SD 14.1). Post mean PTA: 16.2 dB (SD 17.1) ABG ( Pre: 95.8% Post: 95.1% | x | x | x | x | x | Tegmen mastoideum Defect: 4/24 Temporary facial weakness: 1/24 | x | ||
| Ward et al. ( | 0.25–8 kHz (n 2–8 kHz: significant increasein mean thresholds 0.25–4 kHz (n BC: Pre Mean PTA: 8.4 dB (SD 10.4) 7–10 days: 19.2 dB (SD 10.4) >1 month: 16.4 dB (SD 18.8) 0.25–2 kHz (n ABG: Pre: 16.0 dB (SD 7.6) 7–10 days: 16.4 dB (SD 11.1) >1 months: 8.1 dB (SD 8.4) Speech Discrimination Score, % (SD) (n Pre: 98.6 (SD 4.1) 7–10 days: 94.4 (SD 14.5) >1 months: 93.1 (SD 19.6) | x | x | x | x | x | Hemotympanum/middle ear effusion (7–10 days post): 84% Subgroup had significantly larger ABG: 18.1 dB (SD 11.4) vs. 8.8 dB (SD 3.9) | x | ||
| Agrawal et al. ( | x | x | VOR gain Horizontal: >0.7 OR clinically normal: Pre: 18/18 1 week post: 11/18 |>6 weeks post: 16/18 | x | x | x | x | x | ||
| Crane et al. ( | ABG (largest): Pre: 25.83 dB (usually 0.25 kHz) Post: 15.55 dB (frequency not reported) Hearing (n Decreased: 11/18 Increased: 3/18 No change: 4/18 | cVEMP Pre mean: 67.5 dB Post mean: 69.1 (absent in 2) Increased: 5/6, unchanged: 1/6 Normal: >80 dB nHL | x | x | x | x | x | |||
| Crane et al. ( | 0.25–8 kHz (n AC: mean ↑: 10 ± 23 dB (range −45 to +45 dB) 0.25–4 kHz BC: mean: not reported | cVEMP Pre ( Threshold <85 dB: 16/19 Post ( Absent: 10/11 | x | x | x | x | x | |||
| Carey et al. ( | x | x | VOR gain (n Horizontal: Pre: 0.94 ± 0.07 Post: 0.90 ± 0.24 % Change −5% ( Superior: Pre: 0.75 ± 0.13 Post: 0.42 ± 0.11 % Change: −44% ( Posterior: Pre: 0.84 ± 0.09 Post: 0.73 ± 0.20 % Change: −13% ( | x | x | x | Epidural hematoma: 1/19 Cellulitis of the wound: 1/19 Transient diabetes insipidus: 1/19 | x | ||
| Phillips et al. ( | (Frequencies not reported) (n AC, BC: correction of pseudo-conductive hearing loss: 4/5 Residual (>4 months): none | cVEMP Pre: 65 dB (60–70) Post: 82 dB (75–90) Normalized: 5/5 | x | x | x | 4 months | Vertigo: Transient: 4/5 Persistent: 1/5 | x | ||
| Limb et al. ( | 0.25–8 kHz (n AC: no sign.change 0.5–4 kHz BC: no sign.change 0.25–8 kHz (n ABG: partial closure: 5/29 1. No surgical history (n Pre: 96.5 ± 5.0% Post: 96.8 ± 3.8% ( 2. Prev. MEE/PE tube (n Pre: 98 ± 2.3% Post: 99 ± 2.1% ( 3. Prev. stapes procedures (n Pre: 98.7 ± 2.3 Post: 65 ± 56.6%( | x | x | x | x | x | x | x | ||
| R | Hillman et al. ( | 0.5–3 kHz (n AC, BC not reported ABG >10 Pre: 2/16 Post: 2/2 decreased | x | x | x | x | >3 months | Reoccurrence of symptoms after 5 months due to a shift of the bone cement: 1/14 | x | |
| Transmastoid | P | Van Haesendonck et al. ( | 0.5–4 kHz (n AC: Pre median PTA: 25 dB post median PTA: 18 dB Median change: 1 dB BC PTA: Pre median PTA: 11 dB Post: 16 dB Median change: −4 dB ABG Pre: 13 dB Post: 5 dB(median change:8 dB) | x | x | x | x | 1–6 months | Posterior canal BPPV: 2/12 (solved through Epley maneuver) | x |
| Beyea et al. ( | x | x | x | x | x | x | Temporary vertigo: 16/16 Dural tear: 2/16 (low-lying tegmen both cases) | x | ||
| Agrawal and Parnes ( | 0.25–8 kHz (n AC, BC: not reported ABG: decreased: 1/2 | x | x | x | x | Temporary vertigo: 3/3 Dural tear: 1/3 | x | |||
| P + R | Fiorino et al. ( | (Freq. not reported) (n AC, BC: PTA change <10 dB: 4/6 Conductive hearing loss: Unchanged: 1/1 Newly developed due to MEE: 1/6 | VEMP Thresholds (n = 6) Pre Mean: 74 dB (1 absent) Post: >90 dB nHL: 5/6 Stayed absent: 1/6 | x | Procedure not described ( Reduced caloric response: 2/6 | Procedure not described ( Present: 0/6 | 1.5–2 months | Pneumonia: 2/6 | 2–5 | |
| R | Amoodi et al. ( | 0.25–8 kHz (n | x | x | x | Procedure not described ( Present: 0/4 | Not reported. Follow-up: 1.5–4 years | Temporary vertigo: 4/4 | <1 | |
| Lundy et al. ( | (Freq. not reported) (n AC, BC: not reported | x | x | x | x | >3 months | x | <12 h: 13/37 24 h: 24/37 | ||
| Transcanal | RW | Silverstein et al. ( | x | x | x | x | x | x | x | |